Press release
Clinical Radiation Oncology Training at Mannheim Medical Centre, Germany
New Delhi, June 17, 2011 : Dharamshila Hospital And Research Centre has recently acquired a new Elekta Synergy Linear Accelerator capable of IMRT, IGRT, SRS, SRT and SBRT. The clinical and technical application training of this machine is usually scheduled at a teaching Hospital in Germany. Dr. Hari Mohan, Consultant – Radiation Oncology, Dharamshila Hospital visited Mannheim Medical Centre, Germany for clinical training on Elekta Synergy.Mannheim Medical Centre, Germany is affiliated to University of Heidelberg, Germany, the oldest university of Germany. The department of Radiation Oncology at this hospital is equipped with CT simulator, 3 Linear Accelerators, intraoperative Brachytherapy for breast, head and neck and pelvic tumors and interstitial Brachytherapy with iodine seeds for prostate cancer.
He has received a first hand experience of treatment planning with VMAT on Monaco planning system. It was enlightening to know the protocols and planning methodology being used at this centre. All the patients undergo CT simulation as a routine and are planned for radiotherapy with utmost care and compassion. Respiratory gating is used for tumors of lung, breast and chest wall.
The treatment is planned with Oncentra Masterplan, for 3D-conformal radiotherapy and with 5 different inverse treatment planning systems (Corvus, Oncentra Masterplan and preciseplan exclusively for static IMRT, Ergo+++ for VMAT treatments and Monaco for both static and VMAT treatments).
He saw IGRT being performed with stereotactic ultrasound and with X-ray volume imaging (Cone Beam CT, Elekta XVI on Elekta synergy).
Treatments were recorded with the MOSAIQ Electronic Medical Record (EMR) of the patient. MOSAIQ oncology PACS archives all critical data.
IMRT was used for the treatment of almost all patients of Head and neck, prostate and stomach. Tumor relapses near the spine were also treated with IMRT. IGRT protocols are strictly followed for all IMRT patients.
He got experience in Extracranial frameless SRT with image guidance (IGRT). In addition, LDR brachytherapy for prostate cancer is also available.
The department actively collaborates with other departments within the framework of Comprehensive Cancer Centre. This was very similar to the tumor board meeting which we routinely conduct at our hospital wherein every new cancer patient’s management plan collaboratively is arrived at after a joint meeting with Radiation, Medical and surgical oncologists together with oncopathologist and imaging oncology experts.
We at Dharamshila Hospital, have the same setup for Radiotherapy treatment and planning. In addition, we also have Nucletron HDR Brachytherapy facilities which are not there at Mannheim Medical Centre. It is indeed a pleasure to realize that we have the same world class technology which is available at most of the top institutes all over the world. We have been treating our patients with IMRT for the last 6 years and IGRT with VMAT is also now fully functional. That brings us at par with some of the best Radiotherapy departments across the globe. And we sincerely hope that the treatment outcome of our cancer patients will now also be at par with the best internationally accepted standards.
A group of concerned relatives and friends of cancer patients felt the need to provide complete cancer treatment under one roof. They felt it was their Dharma (duty) to provide to cancer patients what was not available to their near and dear ones when they suffered with cancer.
Dharamshila Hospital and Research Centre
Dharamshila Marg, Vasundhara Enclave
Delhi - 110096, INDIA
Email- contact@dhrc.in
Website - http://www.dhrc.in
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Clinical Radiation Oncology Training at Mannheim Medical Centre, Germany here
News-ID: 179890 • Views: …
More Releases from Dharamshila Hospital and Research Centre

Haplo-Identical Bone Marrow Transplantation, “The Glass is Always Half Full”
A 25 year old IT professional was struck with Hodgkin ’s disease which is one of the most curable cancers. He was treated with standard chemotherapy and the disease went away only to reappear a few months later. This time he received local radiation and Autologous Bone Marrow Transplantation (BMT). However, the response was shortlived and the cancer sprung its ugly head within 6 months.
The young man and his distraught…

Most Promising Healthcare Chain 2014 for Dharamshila Hospital & Research Centre
Eminent Healthcare Expert Dr Sandeep Chatrath receives the prestigious India’s Most Promising Healthcare Chain 2014 for Dharamshila Hospital & Research Centre ILc Power Brand 2014.
Dr Sandeep Chatrath also declared by the Jury as the CEO of the Year Healthcare 2014 at Asia’s Biggest Leadership Event, the 5th Annual India Leadership Conclave 2014
The prestigious & coveted Awards were presented in a glittering award ceremony…
More Releases for IMRT
[Latest] Intensity Modulated Radiotherapy Market Overview: Importance, Trends, a …
Intensity Modulated Radiotherapy Market: Outlook and Investment Analysis
Q1: What is the current market outlook for Intensity Modulated Radiotherapy (IMRT)?
The Intensity Modulated Radiotherapy market is experiencing robust growth driven by the rising prevalence of cancer worldwide and increasing demand for advanced, targeted cancer treatment options. IMRT offers precise radiation delivery, minimizing damage to surrounding healthy tissues, which significantly improves patient outcomes. Technological advancements, such as integration with imaging techniques and AI-based…
Rising Government Support and Demand for Non-Invasive Cancer Treatments Fuel Gro …
The global market for Intensity Modulated Radiotherapy (IMRT) was valued at USD 2.21 billion in 2022 and is projected to grow steadily at a compound annual growth rate (CAGR) of 5.4% over the coming years, according to a recent report by Emergen Research. This growth is largely driven by increasing government support for cancer management and a growing preference for non-invasive cancer treatments.
IMRT is a sophisticated technology that customizes radiation…
Intensity-modulated radiotherapy (IMRT) Market Trends, Key Players, DROT, Analys …
The global intensity-modulated radiotherapy (IMRT) market size was estimated at USD 2.1 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 5.2% from 2023 to 2032. The growth of this market is driven by several factors, including the increasing incidence of cancer, technological advancements in radiation therapy, and the rising demand for precise and personalized cancer treatment. Intensity-modulated radiotherapy, commonly referred to as…
Intensity Modulated Radiotherapy Market worth $3.32 billion by 2030, growing at …
The "Intensity Modulated Radiotherapy Market by Indication (Breast Cancer, Gastrointestinal Cancer, Gynecological Cancer), Radiation Type (Carbon-Ion Radiation, Electron Radiation, Photon Radiation), End-User - Global Forecast 2024-2030" report has been added to 360iResearch.com's offering.
The Global Intensity Modulated Radiotherapy Market to grow from USD 2.30 billion in 2023 to USD 3.32 billion by 2030, at a CAGR of 5.36%.
Request a Free Sample Report @ https://www.360iresearch.com/library/intelligence/intensity-modulated-radiotherapy?utm_source=openpr&utm_medium=referral&utm_campaign=sample
The Intensity Modulated Radiotherapy (IMRT) constitutes a significant…
Intensity Modulated Radiotherapy Market stood USD 1.82 Bn in 2022, Projected CAG …
The global healthcare landscape has witnessed a profound surge in the demand for advanced cancer treatment options, notably in the realm of Intensity Modulated Radiotherapy (IMRT). TechSci Research's report, "Intensity Modulated Radiotherapy Market - Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2028", has illuminated the robust standing of the Global Intensity Modulated Radiotherapy Market, which stood at USD 1.82 billion in 2022, and anticipates a steady growth trajectory…
Intensity-modulated Radiotherapy Market worth $2.8 billion by 2028
Intensity-modulated Radiotherapy Market in terms of revenue was estimated to be worth $2.2 billion in 2023 and is poised to reach $2.8 billion by 2028, growing at a CAGR of 5.2% from 2023 to 2028 according to a new report by MarketsandMarkets™. The expansion of the Intensity-modulated radiotherapy market is propelled by several synergistic factors, including robust healthcare infrastructure, escalating cancer prevalence, conducive reimbursement policies, technological innovations, active research initiatives,…